Phenolic-rich extruded BRS 305 sorghum beverage improves cardiometabolic markers and oxidative balance in overweight adults
Daily intake of extruded sorghum beverage for 10 weeks was associated with within-group improvements in insulin, triglycerides, HOMA-IR, and plasma antioxidant capacity in overweight adults on a hypocaloric diet.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The sorghum group showed within-group reductions in insulin, triglycerides, HOMA-IR, and TyG index, increased HDL-c and total plasma antioxidant capacity, and higher plasma concentrations of trans-caffeic acid and naringenin at endpoint. The control group showed within-group reductions in nitric oxide and increased body fat percentage. Oxidative stress markers (superoxide dismutase and malondialdehyde) decreased within the sorghum group.
How it was done
Single-blind, randomized, placebo-controlled trial in 51 overweight adults assigned to a sorghum beverage (n=25) or control beverage (n=26) consumed daily for 10 weeks alongside a personalized hypocaloric diet (-500 kcal). Anthropometry, body composition, biochemical, antioxidant, plasma metabolite, fecal pH, short-chain fatty acids, and Bristol stool scale were assessed at baseline and endpoint.
Risk of bias
Single-blind design limits performance bias control. The small sample (n=51) and 10-week follow-up are insufficient for hard cardiovascular outcome inferences. Within-group comparisons without robust between-group statistical significance require cautious interpretation.
What this study does NOT prove
The study does not prove that the sorghum beverage alone reduces cardiovascular risk or improves body composition independently of the hypocaloric diet.
In clinical practice
Results do not support isolated clinical recommendation of the beverage; the concurrent hypocaloric diet effect cannot be disentangled from the intervention. Larger trials without caloric restriction are needed.
Limitations
Single-blind design limits performance bias control. The small sample (n=51) and 10-week follow-up are insufficient for hard cardiovascular outcome inferences. Within-group comparisons without robust between-group statistical significance require cautious interpretation.
Technical appendix
Version history
- 1.0 · 2026-07-07 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.